In a groundbreaking UK-led clinical trial, patients with certain colorectal cancers treated with just nine weeks of immunotherapy before surgery have remained free of cancer for nearly three years, challenging the current standard of postoperative chemotherapy.
- 59% of patients had no detectable cancer after immunotherapy and surgery.
- None of the patients relapsed after 33 months of follow-up.
- Personalized blood tests help predict treatment success.
What happened
Researchers in the UK conducted the NEOPRISM-CRC trial focusing on patients with stage two or three colorectal cancer featuring a specific genetic subtype (MMR deficient/MSI-high). Instead of the usual approach — surgery followed by several months of chemotherapy — patients received nine weeks of the immunotherapy drug pembrolizumab before their surgery.
The results were striking: 59% of patients had no detectable cancer at the time of surgery, and after nearly three years of monitoring, none experienced a cancer relapse. This contrasts sharply with standard care, where about one in four patients may see cancer return within three years.
Why it feels good
This new approach not only offers a more effective outcome but also reduces the need for months of chemotherapy, which can carry significant side effects. The long-lasting remission observed suggests the immune system is better equipped to control the disease after this pre-surgery boost.
Moreover, scientists have developed personalized blood tests that track tumor DNA, enabling doctors to identify early whether the treatment is working. This could lead to more customized treatment plans and reduce unnecessary therapy for patients who respond well.
What to enjoy or watch next
With colorectal cancer being the fourth most common cancer in the UK, this trial opens exciting possibilities for broader application and improved patient outcomes. Ongoing research will explore how these immune-based therapies can be refined for different patient groups and extended to other cancers.
Future studies will also focus on improving blood testing methods and immune profiling, which may soon become key tools for doctors worldwide in personalizing cancer care and increasing the chances of long-term survival.